increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norelgestromin: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norethindrone Acetate: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norethindrone: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norethindrone; Ferrous fumarate: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norgestimate: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethinyl Estradiol; Norgestrel: (Moderate) Use caution if coadministration of ribociclib with ethinyl estradiol is necessary, as the systemic exposure of ethinyl estradiol may be increased resulting in an increase in estrogenic-related adverse reactions (e.g., nausea, breast tenderness). Ribociclib is a moderate CYP3A4 inhibitor and ethinyl estradiol is a CYP3A4 substrate.
Ethosuximide: (Moderate) Use caution if coadministration of ribociclib with ethosuximide is necessary, as the systemic exposure of ethosuximide may be increased re |
